Comparative Pharmacology
Head-to-head clinical analysis: SODIUM FLUORIDE F 18 versus SODIUM IODIDE I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM FLUORIDE F 18 versus SODIUM IODIDE I 131.
SODIUM FLUORIDE F-18 vs SODIUM IODIDE I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positron-emitting radionuclide used for bone imaging; fluoride ion is incorporated into bone matrix via chemisorption onto hydroxyapatite crystals, reflecting blood flow and osteoblastic activity.
Sodium iodide I 131 is a radioactive isotope that emits beta particles and gamma rays. It is taken up by the thyroid gland via the sodium-iodide symporter and incorporated into thyroid hormones. The beta radiation causes local destruction of thyroid tissue, reducing hormone production and treating hyperthyroidism or thyroid cancer.
2-10 mCi (74-370 MBq) intravenous bolus injection, single dose for positron emission tomography (PET) bone imaging.
For thyroid ablation or therapy of thyrotoxicosis: 100-200 mCi (3.7-7.4 GBq) orally as a single dose. For diagnostic imaging: 5-10 μCi (0.185-0.37 MBq) orally.
None Documented
None Documented
The terminal elimination half-life is approximately 2-4 hours. Clinically, this allows for imaging within 1-3 hours post-injection.
Physical half-life: 8.02 days. Effective half-life in euthyroid patients: ~5-7 days, but reduced to ~3-5 days in hyperthyroidism due to increased turnover. In thyroid cancer with remnant ablation, effective half-life may be longer (up to 8 days) due to reduced clearance.
Renal (primarily). Approximately 70% of the administered dose is excreted unchanged in urine within 24 hours. Less than 10% is excreted in feces.
Primarily renal; approximately 90% excreted in urine within 72 hours, with the remainder eliminated via feces (biliary-fecal route, <10% in bile).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical